Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Recurrence 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Neoplasms 1Lymphoproliferative Disorders 1Immunoproliferative Disorders 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Amyloidosis 1

Interventions

trametinib 4dabrafenib 4encorafenib 3Oxaliplatin 3zolbetuximab 2selpercatinib 2pembrolizumab 2lenvatinib 2larotrectinib 2dostarlimab 2binimetinib 2Leucovorin 2Fulvestrant 2Fluorouracil 2Cetuximab 2Capecitabine 2trastuzumab deruxtecan 1tepotinib 1telisotuzumab vedotin 1ribociclib 1repotrectinib 1relatlimab 1pralsetinib 1pegaspargase 1niraparib 1blinatumomab 1avelumab 1asparaginase erwinia chrysanthemi recombinant 1adagrasib 1Vemurafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Neoplasms × Dexamethasone × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡